Galen Health provides AI teammates designed to automate and enhance multidisciplinary tumor board processes. The platform assists clinicians by running patient data against clinical trial inclusion/exclusion criteria for better treatment planning. It also supports administrators by summarizing meeting notes and action items, saving significant time for care teams.
Funding
Funding not disclosed
Founders
Product
Problem
Pancreatic cancer is often diagnosed late due to a lack of early symptoms and reliable screening methods, resulting in low survival rates. Current detection methods often identify the disease after it has already spread, significantly reducing treatment effectiveness.
Solution
Galen Health's OncoSight is an AI-driven screening system designed to integrate with electronic health records (EHRs) to identify individuals at high risk for pancreatic cancer. By leveraging AI, OncoSight aims to enable earlier detection of the disease, when treatment is most effective, and significantly increase survival rates. The system analyzes patient data within the EHR to identify patterns and indicators associated with pancreatic cancer, providing healthcare providers with actionable insights. This proactive approach allows for timely intervention and improved patient outcomes.
Target Audience
The primary target audience includes healthcare providers, hospitals, and medical institutions seeking to improve early detection rates and patient outcomes for pancreatic cancer.
Features
- AI-powered analysis of electronic health records to identify high-risk individuals
- Seamless integration with existing EHR systems for efficient data processing
- Identification of patterns and indicators associated with early-stage pancreatic cancer
- Actionable insights for healthcare providers to facilitate timely intervention